Bonus Issue, Dividend Likely On May 14: Pharma Stock Rises 177% In 1-Yr, FII Stake Soars

Small cap Pharmaceutical sector company Gujarat Themis Biosyn Ltd today scheduled its meeting of Board of Directors for May 14, 2024 to consider & approve financial results, dividend, and bonus issue to the equity shareholders of the company. Last trading price of Gujarat Themis Biosyn share on BSE is Rs 404.90 per share with intraday fall of 0.50%.

Gujarat Themis Biosyn shares gave return of 86% in last 6-months and soared 334% in last 2-years. It is worth noting that FII/FPI have increased holdings from 0.86% to 1.05% in March 2024 quarter. More details below:

Gujarat Themis Biosyn To Consider Financial Results, Dividend, Bonus On May 14: As per the regulatory filing of Gujarat Themis Biosyn dated May 3, "a meeting of Board of Directors of Gujarat Themis Biosyn Limited is scheduled to be held on Tuesday, 14th May, 2024 inter alia, to transact the following business:
1. To consider and approve the Audited Financial Results for the Quarter/Year ended on 31st March, 2024.
2. To consider recommending Dividend, if any on the equity shares of the Company for the financial year 2023-24.
3. To consider proposal for the Issue of Bonus Shares to the equity shareholders of the Company."

Gujarat Themis Biosyn Share Performance: The 52-week high price of Gujarat Themis Biosyn share on BSE is Rs 423.00 per share (as on 24/04/2024) and 52-week low price is Rs 145.80 per share (as on 26/05/2023), respectively. The market capitalisation of the company is Rs 2941.34 crore. Gujarat Themis Biosyn shares gave return of 50% year-to-date, rose 176% in last 1-year, and surged 717% in last 3-years. In last 5-years, Gujarat Themis Biosyn share surged 4837% and 20,988% in last 10-years.

Gujarat Themis Biosyn Shareholding: Promoters holding remains unchanged at 70.86% in March 2024 quarter. Number of FII/FPI investors increased from 10 to 13 in March 2024 quarter. Mutual Funds have increased holdings from 0.02% to 0.80% in Mar 2024 quarter. Number of MF schemes increased from 3 to 4 in Mar 2024 quarter.

Gujarat Themis About: It was incorporated in 1981 as a joint sector company with GIIC Ltd and Chemosyn (P) Ltd. The company started production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug Companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. The Company entered into Technical & Financial collaboration with Yuhan Corporation, South Korea. With Yuhan's know-how, GTBL became India's first Company to start commercial production of Anti-tuberculosis drug Rifampicin, according to its official website.

Disclaimer: The stock just highlights the dividend, Q4 results, bonus issue is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.